Effects of Fruit Consumption on Risk Factors of Chronic Disease
A Randomized Controlled, Crossover in Design, Double Blind Clinical Trial Investigating the Effects of Whole Versus Processed Fruit Consumption on Risk Factors for Chronic Disease and Performance Indicators.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Berkshire
-
Reading, Berkshire, United Kingdom, RG2 9AR
- University of Reading
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Males due to potential hormonal fluctuations in female subjects
- Aged 30-65years
- Fasting total cholesterol in the upper half of the normal range (6.0-8.0 mmol/l) or triacylglycerol >0.8 mmol/l or a BMI 25-32 kg/m2.
- Not having suffered a myocardial infarction/stroke in the past 12 months
- Not diabetic (diagnosed or fasting glucose > 7 mmol/l) or suffer from other endocrine disorders
- Not suffering from renal or bowel disease or have a history of choleostatic liver or pancreatitis
- Not on drug treatment for hyperlipidaemia, hypertension, inflammation or hypercoagulation
- No history of alcohol misuse
- Not planning or on a weight reducing regime
- Not taking any fish oil, fatty acid or vitamin and mineral supplements
- Non smokers
- Not suffering from depression as indicated by the Brief Symptom Inventory (Appendix 11).
- Not suffering from mild cognitive impairment or dementia according to the MMSE (score ≥ 25).
Exclusion Criteria:
- Females
Medication for hypertension, hyperlipidaemia, inflammation or hypercoagulation
- Hypertension - ACE Inhibitors (e.g. Captopril, Cilazapril), Angiotensin Receptor Blockers (Valsartan), Calcium Channel Blockers (Amlodipine, Nicardipine), Diuretics (Chlortalidone) or Beta blockers (Sotalol, Bisoprolol).
- Cholesterol lowering (Pravastatin, Simuvustatin)
- Anticoagulants (Warfarin)
- Inflammation - NSAID's (Tiaprofenic acid, Sulindac, Ibuprofen), Corticosteroids(Betamethasone)
- Strict vegetarians
- Smokers
- Those on or planning a weight reducing regime
- Blood glucose, haemaglobin or liver enzymes outside of the normal range
- Unable to consume study meals
- Those suffering from depression as indicated by the Brief Symptom Inventory (Appendix 11).
- Those suffering from mild cognitive impairment or dementia as indicated by the MMSE (score < 25).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Placebo Comparator: Control
macro- and micro-nutrient matched control (240 ml)
|
|
|
Experimental: Orange juice
commercial orange juice (240 ml)
|
|
|
Experimental: whole orange
whole orange fruit (240 ml)
|
|
|
Experimental: processed whole orange
processed whole orange (240 ml)
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Flow mediated dilation
Time Frame: change in Flow Mediated Dilation response between baseline and 6 hours
|
change in Flow Mediated Dilation response between baseline and 6 hours
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Postprandial plasma glucose
Time Frame: change in glucose from baseline to 2 hours
|
change in glucose from baseline to 2 hours
|
|
Postprandial insulin
Time Frame: change from baseline to 2 hours
|
change from baseline to 2 hours
|
|
global cognitive function
Time Frame: change from baseline to 6 hours
|
change from baseline to 6 hours
|
|
Blood pressure
Time Frame: change from baseline to 6 hours
|
change from baseline to 6 hours
|
|
postprandial non-esterified fatty acids
Time Frame: change from baseline to 6 hours
|
change from baseline to 6 hours
|
|
Postprandial triacylglycerol
Time Frame: change from baseline to 6 hours
|
change from baseline to 6 hours
|
|
total HDL/LDL
Time Frame: change from baseline to 6 hours
|
change from baseline to 6 hours
|
|
Inflammatory status (IL1-beta; IL2; IL6; IL10; IFN-gamma; TNF-alpha; CRP)
Time Frame: change from baseline to 6 hours
|
change from baseline to 6 hours
|
|
LDL oxidation
Time Frame: change from baseline to 6h
|
change from baseline to 6h
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Plasma flavanone metabolites
Time Frame: change from baseline to 6 hours
|
change from baseline to 6 hours
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- UOR-0001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.